168 related articles for article (PubMed ID: 38146642)
21. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer.
Schöne N; Kemper M; Menck K; Evers G; Krekeler C; Schulze AB; Lenz G; Wardelmann E; Binder C; Bleckmann A
J Extracell Vesicles; 2024 Mar; 13(3):e12418. PubMed ID: 38453684
[TBL] [Abstract][Full Text] [Related]
23. Protein kinase Cι mediates immunosuppression in lung adenocarcinoma.
Yin N; Liu Y; Weems C; Shreeder B; Lou Y; Knutson KL; Murray NR; Fields AP
Sci Transl Med; 2022 Nov; 14(671):eabq5931. PubMed ID: 36383684
[TBL] [Abstract][Full Text] [Related]
24. Extracellular vesicle-mediated immunoregulation in cancer.
Yamamoto T; Yamamoto Y; Ochiya T
Int J Hematol; 2023 May; 117(5):640-646. PubMed ID: 35951282
[TBL] [Abstract][Full Text] [Related]
25. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
[TBL] [Abstract][Full Text] [Related]
26. The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.
Zhu P; Kang G; Jiao Y; Gui C; Fan H; Li X; Jia Y; Zhang L; Ma X
Hum Cell; 2022 Jul; 35(4):1207-1218. PubMed ID: 35593989
[TBL] [Abstract][Full Text] [Related]
27. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma.
Lin M; He J; Zhang X; Sun X; Dong W; Zhang R; Xu Y; Lv L
J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115693
[TBL] [Abstract][Full Text] [Related]
28. Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.
Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1410-1420. PubMed ID: 36852791
[TBL] [Abstract][Full Text] [Related]
29. FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation.
Tian T; Xie X; Yi W; Zhou Y; Xu Y; Wang Z; Zhang J; Lin M; Zhang R; Lv Z; Li X; Lv L; Xu Y
Cell Rep; 2023 Nov; 42(11):113362. PubMed ID: 37938970
[TBL] [Abstract][Full Text] [Related]
30. HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma.
Liu L; Zhang Z; Jiang C; Zhu Y; Han R; Wu L; Xu Y
Aging (Albany NY); 2024 Mar; 16(5):4841-4861. PubMed ID: 38446596
[TBL] [Abstract][Full Text] [Related]
31. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
[TBL] [Abstract][Full Text] [Related]
32. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
de Miguel-Perez D; Russo A; Arrieta O; Ak M; Barron F; Gunasekaran M; Mamindla P; Lara-Mejia L; Peterson CB; Er ME; Peddagangireddy V; Buemi F; Cooper B; Manca P; Lapidus RG; Hsia RC; Cardona AF; Naing A; Kaushal S; Hirsch FR; Mack PC; Serrano MJ; Adamo V; Colen RR; Rolfo C
J Exp Clin Cancer Res; 2022 Jun; 41(1):186. PubMed ID: 35650597
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
34. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
[TBL] [Abstract][Full Text] [Related]
35. Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model.
Veerman RE; Akpinar GG; Offens A; Steiner L; Larssen P; Lundqvist A; Karlsson MCI; Gabrielsson S
Cancer Immunol Res; 2023 Feb; 11(2):217-227. PubMed ID: 36546872
[TBL] [Abstract][Full Text] [Related]
36. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
37. Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles.
Khan A; Di K; Khan H; He N; Li Z
Biosensors (Basel); 2022 Apr; 12(5):. PubMed ID: 35624582
[TBL] [Abstract][Full Text] [Related]
38. Localized Imaging of Programmed Death-Ligand 1 on Individual Tumor-Derived Extracellular Vesicles for Prediction of Immunotherapy Response.
Zhang J; Guan M; Lv M; Liu Y; Zhang H; Zhang Z; Zhang K
ACS Nano; 2023 Oct; 17(20):20120-20134. PubMed ID: 37819165
[TBL] [Abstract][Full Text] [Related]
39. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
40. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]